This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Ebola vaccine (CRXL)
Johnson & Johnson
Drug Names(s): Ebola vaccine (Crucell), Ad5.GP(Z+S/G).mt
Description: This single-shot vaccination is based on Crucell's proprietary PER.C6 cell line technology.
Crucell and Johnson & Johnson
Crucell entered into a Cooperative Research and Development Agreement (CRADA) with the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) to jointly develop, test, and manufacture an adenovirus-based Ebola vaccine. Under the terms of the agreement, Crucell has an option for exclusive worldwide commercialization rights to the Ebola vaccine resulting from this collaboration. In August 2002, the CRADA was extended to cover vaccines against Marburg and Lassa infections. In March 2005, Crucell secured an exclusive license to certain patents of the NIH for the development and commercialization of recombinant vaccines against Ebola.
In October 2010, Johnson & Johnson and Crucell announced an agreement whereby Johnson & Johnson, through an affiliate, would acquire all outstanding equity of Crucell that it does not already own for approximately Euro 1.75 billion in a recommended cash tender offer. The...See full deal structure in Biomedtracker
Ebola vaccine (CRXL) News
Pink Sheet FDA Performance Tracker: CBER Approvals
Additional information available to subscribers only: